Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

September 15, 2014 10:17 AM

14 0

NEW DELHI/MUMBAI (Reuters) - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.

Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now be able to make and sell the Sovaldi generic, the company said in a statement.

Also read: Disney raises its bid for Fox to $71 billion

Read more

To category page